Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 6:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 1,866 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Small portion Clear all
Completed Phase 1 Interventional

LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid Tumors

NCT00556088
View directory record Official record
Conditions
Solid Tumors
Interventions
LBH589, Paclitaxel, Carboplatin, Bevacizumab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 30, 2010 · Synced Oct 31, 2026, 6:57 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer

NCT03846310
View directory record Official record
Conditions
Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer, Nonsquamous Nonsmall Cell Neoplasm of Lung, Sensitizing EGFR Gene Mutation
Interventions
Etrumadenant, Zimberelimab, Carboplatin, Pemetrexed, Pembrolizumab
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
8
States / cities
Tucson, Arizona • Fort Myers, Florida • Tavares, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Oct 31, 2026, 6:57 PM EDT
Recruiting Phase 1 Interventional

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

NCT07540572
View directory record Official record
Conditions
ER+, HER 2- Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Castration-resistant Prostate Cancer (CRPC), Microsatellite Stable (MSS) Colorectal Carcinoma
Interventions
IDE574, Fulvestrant injection
Drug
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years to 99 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
11
States / cities
Plantation, Florida • East Brunswick, New Jersey • Lake Success, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 31, 2026, 6:57 PM EDT
Completed Phase 2 Interventional Results available

CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)

NCT01134575
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
CMC-544 (Inotuzumab Ozogamycin), Rituximab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 31, 2026, 6:57 PM EDT
Completed Phase 2 Interventional Results available

A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

NCT04623775
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
Interventions
Nivolumab, Relatlimab, Carboplatin, Cisplatin, Paclitaxel, Nab-Paclitaxel, Pemetrexed
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
29
States / cities
Duarte, California • Orange, California • New Haven, Connecticut + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 31, 2026, 6:57 PM EDT
Completed Phase 2 Interventional Results available

Beating the Blues for Your Heart

NCT01605552
View directory record Official record
Conditions
Depression, Depressive Symptoms, Cardiovascular Disease (CVD), Coronary Artery Disease (CAD), Heart Disease
Interventions
Beating the Blues (BtB), Usual Care
Behavioral · Other
Lead sponsor
Indiana University
Other
Eligibility
40 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 29, 2022 · Synced Oct 31, 2026, 6:57 PM EDT
Completed Not applicable Interventional

A Wheelchair Propulsion Training Program

NCT04009187
View directory record Official record
Conditions
Spinal Cord Injuries, Multiple Sclerosis, Amputation, Spina Bifida
Interventions
In-person wheelchair propulsion training program, 30-minute education session
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 31, 2026, 6:57 PM EDT
Terminated Not applicable Interventional

Pilot Study Using Amide Proton Transfer Magnetic Resonance Imaging Distinguishing Glioma

NCT03843814
View directory record Official record
Conditions
Gliosarcoma, Glioma
Interventions
APT MRI
Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Oct 31, 2026, 6:57 PM EDT
Withdrawn Not applicable Interventional

Auricular Acupuncture as Part of Multimodal Analgesia After Lower Leg Fracture

NCT05984433
View directory record Official record
Conditions
Pain, Postoperative, Fracture, Ankle, Pilon Fracture of Tibia, Foot Fracture
Interventions
Auricular acupuncture
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 31, 2026, 6:57 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

CRT-Guanfacine for SPD

NCT02524899
View directory record Official record
Conditions
Schizotypal Personality Disorder, SPD
Interventions
Cognitive Remediation Therapy, Guanfacine, Placebo
Behavioral · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 31, 2026, 6:57 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of a Non-invasive Brain Compliance Measurement Device

NCT01753921
View directory record Official record
Conditions
Diabetes, Diabetic Ketoacidosis
Interventions
this is not an intervention study, MRI
Other · Device
Lead sponsor
Stanford University
Other
Eligibility
10 Years to 16 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 31, 2026, 6:57 PM EDT
Completed Not applicable Interventional

Yoga Program for Lung Cancer Patients and Caregivers

NCT02196844
View directory record Official record
Conditions
Lung Cancer
Interventions
Hatha Yoga, Questionnaires, Walk Test
Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 31, 2026, 6:57 PM EDT
Completed No phase listed Observational

Communication Training for Caregivers In Advanced Care Planning

NCT04171895
View directory record Official record
Conditions
Primary Malignant Brain Tumors, Advanced Care Planning
Interventions
Questionnaires, Communication training Part 1 (no longer recruiting), Enhanced usual care, Communication training Part II
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Timeline
2019 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Oct 31, 2026, 6:57 PM EDT
Completed Phase 4 Interventional Results available

Accuracy of an Echo-Stress Protocol Using Regadenoson With Speckle Tracking

NCT02130453
View directory record Official record
Conditions
Ischemia
Interventions
Regadenoson
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 31, 2026, 6:57 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Cannabis Consumption and Driving Impairment Assessment on a Closed Course

NCT06059677
View directory record Official record
Conditions
Cannabis Smoking, Driving Impaired
Interventions
Active smoked cannabis, Placebo smoked cannabis
Drug
Lead sponsor
Bayliss J. Camp, PhD
Government
Eligibility
21 Years to 55 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 31, 2026, 6:57 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Moderators and Mediators of Perceptual Learning

NCT05894967
View directory record Official record
Conditions
Cognitive Change
Interventions
C1 - Standard Perceptual Learning (SPL), C2 - Long Training (LT), C3 - Short Staircases (SS), C4 - Mixed Difficulty (MD), C5 - Noise Training (NT), C6 - Training with Flankers (TWF), C7 - Parafoveal Training (PT), C8 - Stimulus Variety (SV), C8a - Complex Features (CF), C9 - Exogenous Attention Training (ExAT), C10 - Endogenous Attention Training (EnAT), C11 - Multisensory Facilitation (MF), No Contact Control
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 85 Years
Enrollment
1,140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
3
States / cities
Riverside, California • Boston, Massachusetts • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 31, 2026, 6:57 PM EDT
Completed Not applicable Interventional

Study of Hypotensive Hematopoietic Malignancy Patients' USCOM Readings

NCT01755000
View directory record Official record
Conditions
Leukemia, Lymphoma, Paraproteinemias, Multiple Myeloma, Myelodysplastic Syndromes
Interventions
USCOM scan, Fluid Bolus
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 2, 2013 · Synced Oct 31, 2026, 6:57 PM EDT
Completed Phase 2 Interventional Results available

Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy

NCT02223819
View directory record Official record
Conditions
Uveal Melanoma
Interventions
Crizotinib
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
4
States / cities
Miami Beach, Florida • New York, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Oct 31, 2026, 6:57 PM EDT
Active, not recruiting Phase 2 Interventional

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

NCT04488081
View directory record Official record
Conditions
COVID-19
Interventions
Remdesivir, Imatinib Mesylate, Dexamethasone, Cenicriviroc, Icatibant, Apremilast, dornase alfa, Celecoxib, Famotidine, IC14, Aviptadil, narsoplimab, Cyproheptadine, Cyclosporine
Drug · Biological
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
36
States / cities
Birmingham, Alabama • Davis, California • Irvine, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 31, 2026, 6:57 PM EDT
Not yet recruiting Not applicable Interventional

Light Utilization COX-Inhibitory Device Therapy for Infant Cardiac Arrest (LUTICA Study). The LUCID Device is Used in the Treatment of Ischemic Brain Reperfusion Injury Caused by Cardiac Arrest in Pediatric Patients.

NCT07556939
View directory record Official record
Conditions
Reperfusion Injury, Post Cardiac Arrest Brain Injury
Interventions
LUTICIA - Light Utilization COX-Inhibitory Device)
Device
Lead sponsor
Mitovation, Inc
Industry
Eligibility
48 Hours to 1 Year
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 31, 2026, 6:57 PM EDT
Recruiting Not applicable Interventional

Implementation of Neuromuscular Electrical Stimulation After Total Knee Arthroplasty

NCT06953375
View directory record Official record
Conditions
Total Knee Arthroplasty, Functional Recovery, Aging, Physical Therapy
Interventions
NMES, Usual Care
Procedure · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
3,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Aurora, Colorado • Murray, Utah
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 31, 2026, 6:57 PM EDT
Not listed Early Phase 1 Interventional

Neuromodulation to Reduce Muscle Stiffness Following Spinal Cord Injury

NCT06274021
View directory record Official record
Conditions
Spinal Cord Injuries, Spinal Cord Injury, Spinal Cord Injury Cervical, Spinal Cord Injury Thoracic
Interventions
Transcutaneous spinal stimulation at 100 Hz, Transcutaneous spinal stimulation at 50 Hz, Transcutaneous spinal stimulation at 50 Hz and single dose of baclofen, Transcutaneous spinal stimulation at 50 Hz and single dose of tizanidine, Sham transcutaneous spinal stimulation
Device · Combination Product
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 31, 2026, 6:57 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Verbal and Written Instruction Versus Verbal and Written Plus Simulation in Patients With Breast Cancer and Their Caregivers

NCT01829984
View directory record Official record
Conditions
Breast Cancer
Interventions
Verbal and Written Instruction, Verbal and Written Plus Simulation
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
19 Years and older
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 4, 2015 · Synced Oct 31, 2026, 6:57 PM EDT
Recruiting Phase 1 Interventional

Alnuctamab for Refractory SLE (LATTE Study)

NCT07219563
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Alnuctamab
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 60 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 31, 2026, 6:57 PM EDT